Meta-Analysis
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 21, 2019; 25(39): 6025-6040
Published online Oct 21, 2019. doi: 10.3748/wjg.v25.i39.6025
Figure 5
Figure 5 Side effect rates between allicin and control groups (intent-to-treat/per-protocol analysis). There was no statistical significance in side effect rates between the allicin group and control group for ITT analysis [5.90% (18/305) vs 9.53% (29/304), odds ratio = 0.61, 95% confidence interval: 0.32-1.16, P = 0.133]. CI: Confidence interval.